FDA supplement brochure
This article was originally published in The Tan Sheet
Executive Summary
A joint CFSAN/ODS brochure titled "What Dietary Supplements Are You Taking? Does Your Health Care Provider Know? It Matters, and Here's Why" offers tools to guide patients conversations about dietary supplements with their healthcare providers. A Nutrition Assessment checklist first helps patients evaluate whether supplement use is appropriate based on their diets, while a supplement diary sets up a scheme to record all the supplements a patient takes. A medication diary encourages patients to list all current Rx and OTC medications. The brochure text twice reminds readers to "not substitute a dietary supplement for a prescription medicine or therapy," and that "some supplements can have unwanted effects before, during and after surgery." The agency had 50,000 copies of the brochure printed, and has distributed roughly 10,000 to date...
You may also be interested in...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.